What Does Seagen Do?

Total employees1215
HeadquartersBothell
Founded1998

Seagen Inc. is a biotechnology company that discovers, develops, and commercializes targeted therapies to treat cancer. A leader in antibody-drug conjugate (ADC) technology, Seagen has developed multiple approved medicines revolutionizing cancer care. Key products include ADCETRIS® (brentuximab vedotin), PADCEV® (enfortumab vedotin), TUKYSA® (tucatinib), and TIVDAK® (tisotumab vedotin). Founded in 1997 as Seattle Genetics and renamed Seagen in 2020, the company has built a strong pipeline of innovative cancer treatments. In December 2023, Pfizer successfully completed its acquisition of Seagen for $43 billion, aiming to significantly accelerate Pfizer's efforts in oncology and leverage Seagen's ADC expertise. Seagen's operations are now being integrated into Pfizer's oncology division.

Where Is Seagen's Headquarters?

Seagen officeSeagen officeSeagen officeSeagen office
*Images sourced via web search. Rights belong to original owners

HQ Function

The Bothell campus served as the central hub for Seagen's research and development, corporate operations, and administrative functions.

Notable Features:

The campus features state-of-the-art laboratory facilities designed for advanced biotechnology research, particularly in antibody-drug conjugate (ADC) development and manufacturing process development.

Work Culture:

Seagen was known for its innovative, science-driven, and patient-focused work culture. Employees often described it as a collaborative environment dedicated to making a significant impact in oncology.

HQ Significance:

The Bothell headquarters was instrumental in Seagen's growth and success, serving as the birthplace for many of its groundbreaking cancer therapies and ADC platform technologies.

Values Reflected in HQ: The headquarters' design and functionality reflected Seagen's commitment to innovation, scientific excellence, and its mission to improve the lives of cancer patients.

Location:

Prior to its acquisition by Pfizer, Seagen established a significant global presence focused on the research, development, and commercialization of its cancer therapies. This included R&D facilities in the US, an international headquarters in Switzerland to manage European and ex-US operations, and a commercial footprint in multiple countries. Its therapies reached patients worldwide through direct sales and partnerships. Post-acquisition, Seagen's global reach and functions are being integrated into Pfizer's extensive worldwide oncology operations.

Street Address:

21823 30th Dr SE

City:

Bothell

State/Province:

WA

Country:

USA

Where Else Does Seagen Operate Around the World?

Zug, Switzerland

Address: Seagen International GmbH, Theilerstrasse 1a, CH-6300 Zug, Switzerland

Manages and supports Seagen's (now Pfizer's) product commercialization and clinical development activities across Europe and other international markets.

South San Francisco, CA, USA

Address: 1 Tower Place, South San Francisco, CA 94080, USA

Focuses on discovery research, translational science, and early-stage clinical development to expand the oncology pipeline.

Buying Intent Signals for Seagen

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Seagen? Meet the Executive Team

As of April 2025, Seagen' leadership includes:

David R. Epstein - Former Chief Executive Officer
Roger Dansey, M.D. - Former President, Research and Development, and Chief Medical Officer
Todd E. Simpson - Former Chief Financial Officer
Charles R. (Chip) Eyler - Former Chief Commercial Officer
Vaughn Himes, Ph.D. - Former Chief Technical Officer

Who's Investing in Seagen?

Seagen has been backed by several prominent investors over the years, including:

Baker Bros. Advisors LP
The Vanguard Group, Inc.
BlackRock, Inc.
State Street Corporation

What Leadership Changes Has Seagen Seen Recently?

Hire0
Exits3

The most significant executive changes at Seagen in the last 12 months were driven by its acquisition by Pfizer, completed in December 2023. This led to the departure or role changes for most of Seagen's top leadership as operations began integrating into Pfizer's oncology division. Pfizer appointed its own leadership to head the combined oncology organization.

Departures

David R. Epstein, Departed as CEO of Seagen upon completion of the acquisition by Pfizer.
Roger Dansey, M.D., Departed from his role at Seagen following the Pfizer acquisition.
Todd E. Simpson, Concluded his role as CFO of Seagen post-acquisition by Pfizer.

New Appointments:

Chris Boshoff, M.D., Ph.D., Dr. Chris Boshoff leads Pfizer's newly expanded oncology organization, which includes the integrated Seagen business and portfolio.

What Technology (Tech Stack) Is Used bySeagen?

Discover the tools Seagen uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Seagen Email Formats and Examples

Seagen, like many corporations, utilized standardized email formats. The most common formats included first initial followed by last name (e.g., jdoe@seagen.com) or first name dot last name (e.g., jane.doe@seagen.com). Post-Pfizer acquisition, communications may transition to Pfizer's email systems for integrated employees.

[first_initial][last]@seagen.com

Format

jdoe@seagen.com

Example

85%

Success rate

What's the Latest News About Seagen?

Pfizer NewsDecember 14, 2023

Pfizer Completes Acquisition of Seagen

Pfizer Inc. announced the successful completion of its acquisition of Seagen Inc. for $229 per share in cash, totaling $43 billion. This strategic move is expected to significantly bolster Pfizer's oncology portfolio and capabilities, particularly in antibody-drug conjugates....more

Pfizer NewsFebruary 28, 2024

Pfizer’s PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as a First-Line Treatment for Adult Patients with Locally Advanced or Metastatic Urothelial Cancer

The U.S. FDA approved PADCEV in combination with KEYTRUDA for patients with locally advanced or metastatic urothelial cancer. This approval converts the accelerated approval to full approval and expands the indication. PADCEV was originally developed by Seagen and Astellas....more

Seagen News (archived)October 2, 2023

Seagen and Genmab Announce FDA Approval of TIVDAK® (tisotumab vedotin-tftv) in Recurrent or Metastatic Cervical Cancer (Full Approval)

Seagen Inc. and Genmab A/S announced that the U.S. FDA granted full approval for TIVDAK® for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This converted the earlier accelerated approval to full approval....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Seagen, are just a search away.